positron-emission-tomography

Documents about positron-emission-tomography

• A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan#808122ClinicalTrials.gov
• Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [<sup>11</sup>C]UCB-J positron emission tomography study#205495Europe PMC
• Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis#882395ClinicalTrials.gov
• Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)#909412ClinicalTrials.gov
• [18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica#969023ClinicalTrials.gov
• Assessment of Positron Emission Tomography to Early Detect Frailty in Onco-geriatry#982059ClinicalTrials.gov
• Quantification of pituitary 5-HT<sub>1B</sub> receptors with positron emission tomography: Negligible specific binding despite conspicuous uptake#250553Europe PMC
• Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications#308335HAL (France)
• Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging#802500ClinicalTrials.gov
• Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5#806026ClinicalTrials.gov
• [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications#826631ClinicalTrials.gov
• RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3#836999ClinicalTrials.gov
• Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET#847798ClinicalTrials.gov
• FMISO-PET in Brain Tumors and SCS Effect#862613ClinicalTrials.gov
• Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity#865107ClinicalTrials.gov
• Positron Emission Tomography/Magnetic Resonance Imaging in Patients#898563ClinicalTrials.gov
• Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients#903232ClinicalTrials.gov
• Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer.#312085HAL (France)
• Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)#854616ClinicalTrials.gov
• [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications#855742ClinicalTrials.gov
• A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study#903471ClinicalTrials.gov
• CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma#1029774ClinicalTrials.gov
• Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using Carbon 11(C-11) Acetate Cardiac Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI)#1046663ClinicalTrials.gov
• Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer#828984ClinicalTrials.gov
• Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives#895630ClinicalTrials.gov
• Reduced dorsal visual stream α2-adrenergic receptor availability is not associated with visuospatial impairment in Parkinson's disease#433342HAL (France)
• Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival#828714ClinicalTrials.gov
• The Diagnostic Value of PET/MRI in Head and Neck Cancer#832740ClinicalTrials.gov
• PET Scan to Study Brain Control of Human Movement#861233ClinicalTrials.gov
• PET-MRI in Chronic Traumatic Brain Injury (CTBI)#914696ClinicalTrials.gov
• Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans#982363ClinicalTrials.gov
• The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer#1009552ClinicalTrials.gov
• A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer#837697ClinicalTrials.gov
• Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib#867757ClinicalTrials.gov
• 18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer#894090ClinicalTrials.gov
• A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)#897558ClinicalTrials.gov
• Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma#832097ClinicalTrials.gov
• Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission Tomography (PET-CT), Breast Ultrasound, and Magnetic Resonance Imaging (MRI) After Neoadjuvant Chemotherapy in Patients With Breast Cancer#864272ClinicalTrials.gov
• Graft Failure and Consequences of Coronary Artery Bypass Graft Surgery#903031ClinicalTrials.gov
• Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers#1030297ClinicalTrials.gov
• Discovery and radiopharmaceutical development of probes for prospective positron emission tomography imaging of malaria#672807University of Pretoria Repository
• Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation#828692ClinicalTrials.gov
• Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A#833170ClinicalTrials.gov
• Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma#1033270ClinicalTrials.gov
• A Pilot Study of Deep Brain Stimulation of the Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder#872051ClinicalTrials.gov
• Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome#848360ClinicalTrials.gov
• Role of F-18 FDG PET-CT in neuropsychiatric systemic lupus erythematosus#450683SUNScholar
• Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma#811317ClinicalTrials.gov
• Positron Emission Tomography in Determining Stage of Esophageal Cancer#853566ClinicalTrials.gov
• An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease#868727ClinicalTrials.gov